An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 14 Jan 2019 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.
- 14 Jan 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2021.
- 14 Jan 2019 Planned initiation date changed from 1 Oct 2018 to 1 Feb 2019.